对外担保管理制度 第一章 总 则 第一条 为规范江苏亚虹医药科技股份有限公司（以下简称"公司"）对外担 保行为，有效防范公司对外担保风险，现根据《中华人民共和国公司 法》《中华人民共和国证券法》《中华人民共和国民法典》等相关法 律、行政法规和规范性文件以及《江苏亚虹医药科技股份有限公司章 程》（以下简称"《公司章程》"），并参照《上市公司监管指引第 8 号——上市公司资金往来、对外担保的监管要求》等中国证监会及 证券交易所的相关规定，特制定本制度。 第二章 担保原则 1 第二条 本制度所称对外担保，是指公司以第三人的身份为债务人（包括公司 的子公司）对于债权人所负的债务提供担保，当债务人不履行债务时， 由公司按照约定履行债务或承担责任的行为。 第三条 本制度所称的子公司是指公司对其拥有实际控制权的控股子公司或 全资子公司。 第四条 以公司本部或子公司名义进行的所有担保，均由公司统一管理，未按 照《公司章程》的规定经由公司董事会或股东大会批准，公司不得对 外提供担保。 第五条 除《公司章程》和本制度规定之外，公司不得以本公司资产为本公司 的股东或其控制的企业的债务提供担保。 第六条 公司对外担保应当遵循合法、审 ...

江苏亚虹医药科技股份有限公司 2024年度"提质增效重回报"行动方案 投资者是市场之本，是资本市场发展的源头活水。上市公司是市场之基， 通过进一步完善治理、信息透明，更加专注主业、优化资源配置，更加稳健经 营，更好回报投资者，是上市公司应尽的责任与义务。为践行"以投资者为本" 的上市公司发展理念，维护江苏亚虹医药科技股份有限公司（以下简称"公司"） 全体股东利益，基于对公司未来发展前景的信心、对公司价值的认可和切实履 行社会责任，公司特制定 2024 年度"提质增效重回报"行动方案，以进一步提 高运营效率、管理水平，不断提高公司核心竞争力，加强投资者关系管理，保 障投资者权益，维护公司股价稳定，树立良好的市场形象。主要措施如下： 一、推进研发和商业化，提高核心竞争力 公司是专注于泌尿生殖系统肿瘤及其它重大疾病领域的全球化专科创新药 公司。秉承"改善人类健康，让生命更有尊严"的企业使命，公司立志成为在 专注治疗领域集研发、生产和商业化为一体的国际领先制药企业，为中国和全 球患者提供最佳的诊疗一体化解决方案。 公司坚持以创新技术和产品为核心驱动力，通过内部完善的研发体系、核 心技术平台和全球药物开发经验专长，深入 ...

中文全称：江苏亚虹医药科技股份有限公司 英文全称：JIANGSU YAHONG MEDITECH CO., LTD. 江苏亚虹医药科技股份有限公司 章 程 二零二四年四月 | 第一章 | 总 | 则 1 | | --- | --- | --- | | 第二章 | | 经营宗旨和范围 2 | | 第三章 | 股 | 份 2 | | 第一节 | | 股份发行 2 | | 第二节 | | 股份增减和回购 8 | | 第三节 | | 股份转让 9 | | 第四章 | | 股东和股东大会 10 | | 第一节 | | 股 东 10 | | 第二节 | | 股东大会的一般规定 13 | | 第三节 | | 股东大会的召集 16 | | 第四节 | | 股东大会的提案与通知 18 | | 第五节 | | 股东大会的召开 19 | | 第六节 | | 股东大会的表决和决议 23 | | 第五章 | | 董事会 28 | | 第一节 | | 董 事 28 | | 第二节 | | 董事会 32 | | 第六章 | | 高级管理人员 38 | | 第七章 | | 监事会 41 | | 第一节 | | 监 事 41 | | 第二节 ...

Stock Incentive Plan - The company implemented a restricted stock incentive plan in 2022, granting a total of 9,790,800 shares, accounting for 1.72% of the total shares, to 151 employees, representing 38.32% of the total workforce[4] - In 2023, the company granted an additional 1,925,000 restricted shares to 18 employees at a price of 6.79 RMB per share, with 4.22 million shares remaining unallocated and automatically expired[5][8] - The total share-based payment expense recognized in the reporting period for the 2022 restricted stock incentive plan was 16,400,970.53 RMB[9] - Key executives and core technical personnel, including the Chairman and CEO, were granted restricted shares, with the Chairman receiving 1.3 million shares and other executives receiving between 22,500 to 130,000 shares each[12] Financial Performance - Revenue for 2023 reached 13,753,343.12 yuan, a significant increase compared to 2022's 26,095.32 yuan[18] - Net profit attributable to shareholders in 2023 was -400,434,603.65 yuan, a decrease from -246,549,785.26 yuan in 2022[18] - Operating cash flow for 2023 was -398,186,688.82 yuan, down from -241,960,907.88 yuan in 2022[18] - Total assets at the end of 2023 were 2,632,270,467.20 yuan, a decrease of 8.41% compared to 2022[18] - Basic earnings per share for 2023 were -0.70 yuan, compared to -0.43 yuan in 2022[19] - Weighted average return on equity for 2023 was -15.52%, down from -8.52% in 2022[19] - Revenue in Q4 2023 was 10,757,271.87 yuan, the highest among all quarters[23] - Net profit attributable to shareholders in Q4 2023 was -132,390,991.55 yuan, the lowest among all quarters[23] - Government subsidies in 2023 amounted to 6,953,033.26 yuan, an increase from 5,929,193.05 yuan in 2022[24] - Non-recurring gains and losses in 2023 totaled 31,788,811.50 yuan, a decrease from 63,493,965.12 yuan in 2022[27] Asset and Investment Changes - The company's trading financial assets decreased by 1,108,968,660.80 RMB, from 1,703,276,190.24 RMB to 594,307,529.44 RMB, impacting the current profit by 23,932,781.55 RMB[31] - The company's other current assets increased by 14,544,364.54 RMB, impacting the current profit by 1,459,111.24 RMB[31] - The company's other equity instrument investments increased by 805,424.10 RMB, from 15,336,049.20 RMB to 16,141,473.30 RMB[31] Product Development and Clinical Trials - The company has 2 marketed products and 13 products in clinical and preclinical development, including 6 in clinical development, with APL-1702 and APL-1202 being global first-in-class drugs[38] - The company's APL-1202, in combination with tislelizumab, showed a significant increase in histological response rate in a Phase II clinical trial for muscle-invasive bladder cancer[35] - The company is preparing to submit an NDA for APL-1702 to the NMPA and is discussing a Phase III clinical trial plan with the FDA for the US market[35] - APL-1202 combined with chemotherapy for recurrent NMIBC did not meet the primary endpoint in the ACCRUE study, leading to the termination of further development in this indication[75] - In the ASCERTAIN study, APL-1202 monotherapy showed similar non-recurrence rates compared to chemotherapy in untreated intermediate-risk NMIBC patients, with 8 out of 21 patients completing over 1 year of treatment[78] - APL-1202 combined with Tislelizumab in the ANTICIPATE study showed a pCR rate of 39% vs 21% for Tislelizumab alone, with promising efficacy signals in MIBC patients[79] - The ANTICIPATE study is expected to release top-line Phase II data in Q3 2024, with plans to prioritize clinical development in China for advanced bladder cancer[80] - APL-1501, a second-generation product of APL-1202, is undergoing Phase I trials in Australia, aiming to improve efficacy and reduce side effects with better pharmacokinetic properties[83] - The company plans to initiate clinical studies in the US for APL-1501 combined with immune checkpoint inhibitors for BCG-unresponsive NMIBC patients, with discussions with FDA planned for 2024[83] - APL-1202 combined with immune checkpoint inhibitors is expected to improve the efficacy of advanced bladder cancer patients, with a current single-agent ORR of only around 25%[84] - APL-1706, a diagnostic imaging agent for bladder cancer, has been approved in over 30 countries and completed Phase III clinical trials in China, showing a 43.3% additional detection rate of bladder cancer lesions compared to standard white light cystoscopy[85] - APL-1706's Phase III clinical trial demonstrated an additional detection rate of ≥1 CIS lesion in 9.6% of subjects, with real-world studies showing a 7.1% additional detection rate[85] - APL-1706's New Drug Application (NDA) was accepted by the National Medical Products Administration in November 2023, with expected approval by June 2025[88] - APL-1702 showed a significant improvement in response rate by 89.4% compared to placebo (41.1% vs. 21.7%, p = 0.0001) in its Phase III clinical trial[90] - APL-1702 demonstrated a 41.4% improvement in HPV clearance rate in the mITT population (28.0% vs. 19.8%) and a 103.9% improvement for high-risk HPV16 and/or HPV18 (31.4% vs. 15.4%)[90] - APL-1702's Phase III clinical trial results were selected for oral presentations at the 2024 EUROGIN and SGO conferences[91] - APL-1702 Phase III clinical trial enrolled 402 patients from multiple countries including China, Germany, and the Netherlands[120] - The trial evaluates the efficacy and safety of APL-1702 for HSIL, with primary endpoint being response rate at 6 months post-treatment[120] - Response rate and HPV16+/HPV18+ clearance rate were compared between APL-1702 and placebo groups[121] - APL-1702 is expected to redefine the treatment goals for cervical precancerous lesions, shifting focus from one-time surgical outcomes to long-term disease management, aiming to balance treatment risks and benefits while avoiding or delaying invasive surgeries[123] - The company plans to submit a pre-submission communication to the European Medicines Agency (EMA) for APL-1702 in Q3 2024 and aims to discuss registration clinical trial designs with the US FDA for the North American market in 2024[123] - APL-1401, a novel oral drug for ulcerative colitis (UC), is undergoing Ib phase clinical trials in 12 centers across China and the US, with completion expected in 2025[124] - APL-2301, a novel antibacterial drug for Acinetobacter baumannii infections, has been approved for Phase I clinical trials in Australia, focusing on safety, tolerability, and pharmacokinetics[128] - The company is developing APL-2302, a USP1 inhibitor, which has shown strong tumor-killing effects in preclinical studies and is planned for clinical trial applications in 2024[129][130][131] - APLD-2304, a portable blue-light bladder soft scope, is being developed to improve specificity and reduce false positives in bladder cancer diagnosis, with ongoing exploration of overseas commercialization opportunities[132][135] - AT-014, a high-selective growth factor receptor inhibitor, is being optimized using AI technology for treating bladder cancer and other advanced solid tumors[136] - AT-017, an epigenetic-related small molecule oral drug, is being developed for urogenital system tumors, with ongoing lead compound optimization using TAIDD platform[137] - AT-018 is a self-developed small molecule oral drug targeting cell cycle-related pathways, specifically for treating female-related cancers such as breast cancer, ovarian cancer, and endometrial cancer. The company utilizes the TAIDD platform for multi-conformation simulation and AI for compound optimization[138] - AT-020 is a next-generation ADC drug targeting new tumor antigens, with potential to address unmet clinical needs in bladder and breast cancers. Existing ADC drugs like Enfortumab Vedotin show an ORR of 50%-60% in advanced urothelial cancer, indicating significant room for improvement[139] - AT-021 is an ADC drug aimed at enhancing anti-tumor immunity by combining self-developed immune-boosting small molecules with targeted antibodies. It aims to improve efficacy and reduce side effects of current immunotherapies like CTLA-4 and PD-1 antibodies[140] - APL-1702, a photodynamic medical device combination product, is being developed for cervical high-grade squamous intraepithelial lesions, with plans to submit a Phase III clinical trial application to the FDA[146] - APL-1202, targeting MetAP2, is in development for untreated intermediate-risk NMIBC and as a neoadjuvant therapy for MIBC in combination with tislelizumab[146] - APL-1501, a second-generation APL-1202, is being developed for urological tumors, with clinical trials planned in Australia[146] - AT-014 and AT-020 are in development for urological tumors and various solid tumors, respectively, leveraging the TAIDD and ADC platforms[146] - APL-2302, targeting USP1, is being developed for ovarian and breast cancers, with global rights[146] Commercialization and Market Access - The company's oncology division has rapidly built a nearly 200-person commercialization team, aiming for over 100 million RMB in sales and internal break-even in 2024[39] - The company's HCCM platform has over 8,000 users, with more than 85% of registered doctors being from relevant fields, and nearly 1,500 interactions in the breast cancer field[40] - The company achieved sales of 9.2892 million yuan for its oncology products, including Dypate and Ouyoubi, by the end of the reporting period[63] - The company's oncology products, Dypate and Ouyoubi, achieved coverage in 80% of target cities by Q4 2023 and 100% by Q1 2024[68] - Dypate achieved sales in over 70% of target key hospitals within six months of launch, while Ouyoubi connected with major customers and benefited over 1,000 patients within three months of launch[68] - The company's market access team achieved 90% provincial bidding and dual-channel access for its oncology products[68] - The company established a Women's Health Division in early 2024 to focus on the commercialization of APL-1702 and expand its gynecological product pipeline[72] - The company is actively promoting the overseas development and collaboration opportunities for APL-1202/APL-1501 and exploring commercialization opportunities for a disposable blue-light cystoscope in the US clinic market[66] - The company is focusing on localizing production of imported drugs and devices to establish a reliable and agile supply chain while reducing costs[93] - The company is committed to providing optimal diagnostic and therapeutic solutions for bladder cancer, with a product portfolio covering NMIBC diagnosis, surgery, treatment, and follow-up[96] Environmental and Social Responsibility - The company invested 692,300 yuan in environmental protection during the reporting period[49] - The company consumed 1,921.52 tons of water and 908,100 kWh of electricity during the reporting period[51] - The company has implemented strict environmental management systems, including waste classification and hazardous waste disposal through qualified third-party companies[55][56] - The company released its first ESG report in 2023, integrating environmental, social, and governance factors into its strategic development to provide more decision-making information for investors[142] Shareholder and Employee Commitments - Employee stock ownership accounts for 4.28% of the total share capital[102] - Number of employees holding shares is 43, representing 10.91% of the total workforce[103] - Total employee shareholding is 2,437,600 shares[103] - The company has committed to not transferring or entrusting others to manage its shares for 36 months from the date of listing, and will not propose the company to repurchase these shares[155] - If the company's stock price remains below the issue price for 20 consecutive trading days within 6 months of listing, the lock-up period for pre-listing shares will be automatically extended by 6 months[155] - In the event of major illegal activities leading to delisting, shareholders commit not to sell their shares from the date of the administrative penalty or judicial decision until the stock is delisted[155] - Shareholders who violate the share lock-up commitments must publicly explain the reasons and apologize to shareholders and the public, with any illegal gains from share sales to be returned to the company[155] - Certain shareholders, including Pan-Scientific, have committed to a 36-month lock-up period from the listing date, with similar penalties for violations[155] - Other shareholders, such as Taizhou Donghong and Taizhou Yahong, also have a 36-month lock-up period from the listing date, with additional commitments in case of delisting due to illegal activities[157] - Some shareholders, including Nanjing Ruike and QM139, have a lock-up period of 12 months from the listing date or 36 months from the completion of the industrial and commercial registration changes, whichever is longer[157] - Directors and senior management have a 12-month lock-up period from the listing date, with additional restrictions if the company is not profitable at the time of listing[160] - If the company is not profitable at the time of listing, directors and senior management cannot sell their pre-listing shares for 3 full fiscal years, and must comply with relevant regulations even after leaving the company[160] - In case of stock price falling below the issue price for 20 consecutive trading days within 6 months of listing, the lock-up period for directors and senior management will be automatically extended by 6 months[160] - The company's core technical personnel are subject to a 12-month lock-up period from the date of listing, and a 6-month lock-up period after resignation, during which they cannot transfer or entrust others to manage their shares[166] - Core technical personnel can only transfer up to 25% of their pre-IPO shares annually for 4 years after the lock-up period expires[166] - The company's directors, supervisors, and senior management are restricted from transferring more than 25% of their total shares annually after the lock-up period[163] - If the company is not profitable at the time of listing, core technical personnel cannot reduce their pre-IPO shares for 3 full fiscal years[166] - The company's directors, supervisors, and senior management cannot reduce their shares if the company is not profitable at the time of listing for 3 full fiscal years[163] - The company's directors, supervisors, and senior management cannot reduce their shares within 6 months after resignation[163] - The company's core technical personnel cannot reduce their shares within 6 months after resignation[166] - The company's directors, supervisors, and senior management cannot reduce their shares if the company is involved in major illegal activities that trigger delisting[163] - The company's core technical personnel cannot reduce their shares if the company is involved in major illegal activities that trigger delisting[166] - The company's directors, supervisors, and senior management must publicly explain and apologize if they violate the share reduction commitments[163] - The company plans to reduce its shareholding by no more than 100% of its total shares within two years after the lock-up period expires, with the selling price not lower than the audited net asset value per share at the end of the previous fiscal year[173] - The company will initiate stock price stabilization measures if the stock price remains below the audited net asset value per share for 20 consecutive trading days within three years of listing[172] - The company will hold a board meeting within 10 days to pass a resolution on stock repurchase and submit it to the shareholders' meeting for approval if the stock price stabilization conditions are met[172] - The company will use its own funds for stock repurchase, with the repurchase price not exceeding the latest audited net asset value per share[172] - The company will repurchase shares through centralized bidding, tender offers, or other methods approved by securities regulators, with the annual repurchase amount not exceeding 50% of the net profit attributable to the parent company's shareholders in the most recent audited fiscal year[175] - If the company's stock price remains above the audited net asset value per share for three consecutive trading days, the repurchase plan will be terminated[175] - The controlling shareholder's share purchase plan will not exceed 20% of the after-tax cash dividends received from the company in the previous year, and the purchase price will not exceed the audited net asset value per share in the most recent fiscal year[175] - Directors and senior management will purchase shares within 90 days after the controlling shareholder's plan is completed, with the purchase amount not exceeding 20% of their after-tax compensation from the company in the previous year[178] - The company will cancel repurchased shares within 10 days after the completion or termination of the repurchase plan and proceed with the capital reduction process[175] - The company will extend the period for six months after expiration and return the after-tax cash dividends received from the company in the most recent fiscal year. If not returned on time, the company may deduct from future cash dividends until the cumulative deduction reaches the total after-tax cash dividends received in the most recent fiscal year[181] - If directors or senior management fail to fulfill their commitments to stabilize stock prices within three years of listing, they must publicly explain the reasons, apologize, and propose supplementary or alternative commitments. Additionally, 20% of their monthly after-tax salary will be deducted until the cumulative deduction reaches 20% of their after-tax salary from the most recent fiscal year[181] - In case of false statements or major omissions in the prospectus that significantly affect the company's compliance with legal issuance conditions, the company will repurchase all newly issued shares. The repurchase price will be determined according to regulatory documents and will not be lower than the market price at the time of repurchase[181] - If the company violates

江苏亚虹医药科技股份有限公司 第一章 总 则 第一条 为规范江苏亚虹医药科技股份有限公司（以下简称"公司"）与关 联方之间的关联交易，保证公司与关联方之间所发生的交易符合公 平、公开、公正的原则，维护公司与全体股东的合法权益，根据《中 华人民共和国公司法》《上海证券交易所科创板股票上市规则》等 相关法律、法规、规范性文件及《江苏亚虹医药科技股份有限公司 章程》（以下简称"《公司章程》"），并参照中国证券监督管理 委员会（以下简称"中国证监会"）、证券交易所的相关规定，特制 定本制度。 第二章 关联交易和关联人的界定 1 第二条 关联交易是指公司或其合并报表范围内的子公司与公司关联人之 间发生的可能导致转移资源、劳务或义务的行为（不论是否收取价 款），主要包括： （一） 购买或者出售资产； （二） 对外投资（购买银行理财产品的除外）； （三） 转让或受让研发项目； （四） 签订许可使用协议； （五） 提供担保； （六） 租入或者租出资产； （七） 委托或者受托管理资产和业务； （八） 赠与或者受赠资产； （九） 债权、债务重组； （十） 提供财务资助； （十一） 放弃权利（含放弃优先购买权、优先认缴出资权利等） ...

股东大会议事规则 第一章 总 则 公司在上述期限内不能召开股东大会的，应当报告公司所在地中国 证券监督管理委员会（以下简称"中国证监会"）派出机构和上海证 券交易所，说明原因并公告。 1 第一条 为了规范江苏亚虹医药科技股份有限公司（以下简称"公司"）的 行为，保证公司股东大会依法行使职权，根据《中华人民共和国公司 法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简 称"《证券法》"）等相关法律、法规和其他规范性文件及《江苏亚虹 医药科技股份有限公司章程》（以下简称"《公司章程》"）的相关 规定，制定本议事规则。 第二条 公司应当严格按照法律、行政法规、《公司章程》及本议事规则的相 关规定召开股东大会，保证股东能够依法行使权利。 公司董事会应当切实履行职责，认真、按时组织股东大会。公司全体 董事应当勤勉尽责，确保股东大会正常召开和依法行使职权。 第三条 股东大会应当在《公司法》和《公司章程》规定的范围内行使职权。 第四条 股东大会分为年度股东大会和临时股东大会。年度股东大会每年召 开一次，应当于上一会计年度结束后的 6 个月内举行。临时股东大 会不定期召开，出现《公司法》和《公司章程》规定的应当 ...

江苏亚虹医药科技股份有限公司 董事会审计委员会 2023 年度履职情况报告 根据《上市公司治理准则》《上海证券交易所科创板上市公司自律监管指引 第 1 号——规范运作》等法律法规以及《江苏亚虹医药科技股份有限公司章程》 （以下简称"《公司章程》"）等规章制度的要求，我们作为江苏亚虹医药科技股 份有限公司（以下简称"公司"）董事会审计委员会成员，现就 2023 年度履职情 况作如下报告： 一、董事会审计委员会基本情况 公司第一届董事会审计委员会由独立董事张炳辉先生、独立董事秦扬文先生、 董事江新明先生共 3 名委员组成，其中主任委员会由具有专业会计资格的独立董 事张炳辉先生担任。 报告期内，公司第一届董事会任期届满，公司于 2023 年 12 月 28 日召开 2023 年第一次临时股东大会完成换届选举，并同日召开第二届董事会第一次会议，审 议通过《关于选举公司第二届董事会各专门委员会委员及召集人的议案》，选举 产生第二届董事会审计委员会。公司第二届董事会审计委员会由独立董事张炳辉 先生、独立董事王文宁女士和董事江新明先生共 3 名委员组成，其中主任委员由 具有专业会计资格的独立董事张炳辉先生担任。独立董事人数 ...

1 术服务、技术开发、技术咨询、技术交流、技术转让、技术推广；市场营销策划 （除依法须经批准的项目外，凭营业执照依法自主开展经营活动） 二、修订《公司章程》的情况 证券代码：688176 证券简称：亚虹医药 公告编号：2024-028 江苏亚虹医药科技股份有限公司 关于增加经营范围、修订《公司章程》及部分内部 管理制度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏亚虹医药科技股份有限公司（以下简称"公司"）于 2024 年 4 月 17 日 召开第二届董事会第五次会议，审议通过了《关于增加公司经营范围、修订<江 苏亚虹医药科技股份有限公司章程>及部分内部管理制度的议案》。现将有关事 项公告如下： 一、公司经营范围变更情况 根据公司经营发展需要和实际情况，结合公司战略发展规划，拟增加公司经 营范围。 变更前的经营范围：医药产品的技术研发、咨询服务；自营和代理各类商品 及技术的进出口业务（国家限定公司经营或禁止进出口的商品和技术除外）。（依 法须经批准的项目，经相关部门批准后方可开展经营活动）许可项目：药品生产； ...

江苏亚虹医药科技股份有限公司董事会审计委员会 对立信会计师事务所（特殊普通合伙） 2023 年度履行监督职责情况报告 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理 准则》《国有企业、上市公司选聘会计师事务所管理办法》等规定和要求，江苏 亚虹医药科技股份有限公司（以下简称"公司"）董事会审计委员本着勤勉尽责 的原则，恪尽职守，认真履职。现将审计委员会对会计师事务所履行监督职责 的情况汇报如下： 一、2023 年年审会计师事务所基本情况 （一）会计师事务所基本情况 立信会计师事务所（特殊普通合伙）（以下简称"立信"）由潘序伦博士于 1927 年在上海创建，1986 年复办，2010 年成为全国首家完成改制的特殊普通合 伙制会计师事务所，注册地址为上海市，首席合伙人为朱建弟先生。立信是国 际会计网络 BDO 的成员所，长期从事证券服务业务，新证券法实施前具有证券、 期货业务许可证，具有 H 股审计资格，并已向美国公众公司会计监督委员会 （PCAOB）注册登记。 截至 2023 年末，立信拥有合伙人 278 名、注册会计师 2,533 名、从业人员 总数 10,730 名，签署过证券服务业务审计 ...

证券代码：688176 证券简称：亚虹医药 公告编号：2024-027 江苏亚虹医药科技股份有限公司 2023 年度募集资金存放与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要 求》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》及相 关业务规则的规定，江苏亚虹医药科技股份有限公司（以下简称"公司"或"亚 虹医药"）2023 年度募集资金存放与实际使用情况如下： 一、募集资金基本情况 （一）实际募集资金金额和资金到位情况 经中国证券监督管理委员会作出《关于同意江苏亚虹医药科技股份有限公司 首次公开发行股票注册的批复》（证监许可〔2021〕3797 号），并经上海证券交易 所同意，公司于 2021 年 12 月向社会公开发行人民币普通股 110,000,000 股，每 股面值人民币 1.00 元，每股发行价为人民币 22.98 元，募集资金总额为人民币 2,527,800,000.00 元，扣除不含税的发行费用 ...